findmyKOL
Clinical trialNCT02044653CompletedPhase 2Interventional

Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)

SponsorGenexine, Inc.Enrollment257AnemiaChronic Kidney Disease
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

South Korea
  • Bucheon St. Mary'S Hospital

    Bucheon-si, South Korea

  • Bundang Seoul National University College of Medicine

    Gumi, South Korea

  • the Catholic University of Korea Incheon St.Mary'S Hospital

    Incheon, South Korea

  • Gangnam Severance Hospital

    Seoul, South Korea

  • Seoul St.Mary'S Hospital

    Seoul, South Korea

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
15 Apr 2014
Primary completion
20 Apr 2017
Completion
20 Apr 2017
Last update posted
16 Oct 2017
Registered enrollment
257
Registry id
NCT02044653

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.